BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 24950593)

  • 1. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease.
    Okada AA; Goto H; Ohno S; Mochizuki M;
    Arch Ophthalmol; 2012 May; 130(5):592-8. PubMed ID: 22652845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
    Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
    Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
    Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
    Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
    Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
    Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
    Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
    Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behçet's disease.
    Ishikawa S; Taguchi M; Muraoka T; Sakurai Y; Kanda T; Takeuchi M
    Br J Ophthalmol; 2014 Nov; 98(11):1508-13. PubMed ID: 24939422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
    Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
    Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
    Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
    Tognon S; Graziani G; Marcolongo R
    Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
    Yoshida A; Kaburaki T; Okinaga K; Takamoto M; Kawashima H; Fujino Y
    Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.
    Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM
    Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.